Editorial
Clinical implications and future perspectives in testing non-small cell lung cancer (NSCLC) for anaplastic lymphoma kinase (ALK) gene rearrangements
Abstract
Over the last decade different oncogenic drivers have been discovered in non-small cell lung cancer (NSCLC).
Among them, anaplastic lymphoma kinase (ALK) gene rearrangement, due to inversion or translocation of chromosome 2p, has become a new druggable target for anticancer therapy.
Among them, anaplastic lymphoma kinase (ALK) gene rearrangement, due to inversion or translocation of chromosome 2p, has become a new druggable target for anticancer therapy.
